U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06927687) titled 'Study of ZG005 in Patients With Advanced Solid Tumors' on April 07.
Brief Summary: This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
BIOLOGICAL: ZG005 for Injection
Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Publishe...